Hexarelin
Also referenced as: Examorelin
A synthetic hexapeptide GH secretagogue with endocrine and preclinical cardiac research.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Investigational
Not FDA-approved for the research uses discussed; no established clinical enhancement indication.
- Human data
- Limited
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A synthetic hexapeptide GH secretagogue with endocrine and preclinical cardiac research.
Not FDA-approved for the research uses discussed; no established clinical enhancement indication.
Cardiac laboratory findings should not be promoted as a demonstrated heart treatment.
Why It's Being Studied
- GH secretion
- Experimental cardiac signalling
Mechanism of Action
Ghrelin-receptor activation stimulates GH release; additional cardiac mechanisms remain investigational.
Ghrelin-receptor activation stimulates GH release; additional cardiac mechanisms remain investigational. Cardiac laboratory findings should not be promoted as a demonstrated heart treatment.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- GH secretion
- Experimental cardiac signalling
- Injectable clinical research
Evidence Summary
Small human pharmacology studies support acute GH secretion, not lasting recovery or cardiovascular benefit.
Higher tiers carry more weight. Filled tiers have evidence for Hexarelin; tap to read it.
- Small human pharmacology studies support acute GH secretion, not lasting recovery or cardiovascular benefit.
1 cited sources.
- Clinical trial1
Human clinical evidence
- Small human pharmacology studies support acute GH secretion, not lasting recovery or cardiovascular benefit.
Reported Adverse Events in Research
- Effects on prolactin, ACTH and cortisol and poorly characterized long-term safety are important.
Limitations of Current Evidence
- Cardiac laboratory findings should not be promoted as a demonstrated heart treatment.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Hexarelin | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Limited | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Injectable clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Clinical trial
Hexarelin — clinical trial